Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Alluvium Global Fund Stuart Pearce, Alexis Delloye | “Our two healthcare companies had a poor quarter (in terms of share price performance, not business fundamentals). HCA Healthcare, the hospital operator, fell 17.5%. The share price fell 8.8% immediately following its first quarter results (despite management reaffirming its 2026 guidance). We suspect this is a (over) reaction to poorer than expected respiratory volumes due to a mild flu season. With the shares trading at a discount to our valuation we bought a little more to bring the Fund's position to 6.4%.” | NEUTRAL | Q2 2026 Jul 29, 2026 | View Pitch |
Right Tail Capital Jeremy Kokemor | “HCA Healthcare (HCA). It is a high-quality hospital operator that combines dominant local market positions, outstanding operational execution, disciplined capital allocation, and resilient demand. It ” | NEUTRAL | Q2 2026 Jul 15, 2026 | View Pitch |
Alluvium Global Fund Stuart Pearce, Alexis Delloye | “HCA Healthcare reported pleasing results and management upgraded its full year's earnings guidance by 4.8% at the EPS level. With it buying back more shares, and after making some other tweaks, our valuation increased by 5%. But, with a share price increase of 9.7% over the quarter, the premium widened. Both HCA and McKesson account for more than 5% of the Fund. Most readers know that regulatory requirements mean that positions greater than 5% can be troublesome and necessitate trimming. With the share prices of these businesses being at circa 40% premiums to our valuations, and applying subjective considerations, sadly these businesses were deemed to best qualify for the required selling. We did not sell too much of each, and they still account for 5.7% and 6.1% of the Fund respectively. BSD Analysis: HCA is healthcare infrastructure optimized for scale, data, and operational discipline. Hospital demand doesn't disappear — it backs up, then returns with worse acuity and better pricing. Labor pressure is real, but HCA's scale advantage matters more than headlines suggest. Investors fixate on wage inflation and regulatory noise. Yet margin recovery follows volume normalization faster than expected. Data-driven staffing and procurement create advantages smaller systems can't replicate. Cash flow durability supports reinvestment and returns. This is hospital economics run by operators, not idealists.” | BULL | Q4 2025 Jan 23, 2026 | View Pitch |
L1 Capital International Fund David Steinthal | “HCA Healthcare (HCA) is the leading for-profit hospital operator and outpatient services provider in the U.S. In our December 2024 Quarterly Report we outlined our thoughts on why we considered the 25% fall in the share price due to healthcare policy concerns was excessive... Over the first half of 2025 healthcare policy has become clearer and is less negative for HCA than the market had feared. HCA's share price has subsequently increased materially, and we have sold part of our investment, again to actively manage risk adjusted returns. HCA remains a top ten Fund holding at the end of the June 2025 quarter. BSD Analysis: HCA Healthcare is the undisputed, high-quality hospital oligopolist whose stock is a conviction bet on its superior scale and operational efficiency. The core moat is its massive, integrated network of 186 hospitals and 2,000+ sites of care, which grants it significant bargaining power with payers and suppliers. The company is converting its scale into superior financial performance, with Adjusted EBITDA mathbfguidance} raised to $12.8-$13.4 billion. HCA is a defensive compounder, leveraging the non-cyclical demand for healthcare and its operational excellence to deliver predictable, high-quality earnings.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Alluvium Global Fund Stuart Pearce, Alexis Delloye | “HCA Healthcare's solid non-Covid patient volume growth and improved nursing labor conditions led to upgraded earnings guidance. Although the business remains reasonably valued, the manager trimmed the holding slightly purely to fund other attractive opportunities after the stock doubled.” | BULL | Q2 2023 Jul 11, 2023 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
